ArticleFrontiers in public health2022
Inflammatory Indexes for Assessing the Severity and Disease Progression of Ulcerative Colitis: A Single-Center Retrospective Study.
Article in Frontiers in public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 31 citations in OpenAlex.
- Endoscopic Activity Prediction in Ulcerative Colitis Using Hemogram-Derived Inflammatory Indices: Impact of Azathioprine Use on Diagnostic Performance.Journal of clinical medicine · 2026Article
- Association Between the C-Reactive Protein-Albumin-Lymphocyte (CALLY) Index and Tissue-Confirmed Cytomegalovirus Colitis in Patients with Active Ulcerative Colitis.Diagnostics (Basel, Switzerland) · 2026Article
- Diagnostic Performance of Blood-Based Inflammatory Indices, Including a Novel Composite Score, for Estimating Fecal Calprotectin Levels in Pediatric Inflammatory Bowel Disease.Journal of clinical medicine · 2026Article
- Correlation between inflammatory markers and disease severity in ulcerative colitis.World journal of gastrointestinal surgery · 2025Article
- Platelet-to-albumin ratio as an indicator for Crohn's disease activity and severity: a multicentre cross-sectional study.BMJ open · 2025Article
- Assessment of AOPP, TBARS, and Inflammatory Status in Diabetic Nephropathy and Hemodialyzed Patients.International journal of molecular sciences · 2025Article
- Clinical evaluation of platelet-to-albumin ratio as a predictor of surgical site infection in pediatric patients with ulcerative colitis.Surgery today · 2025Article
- Risk factors for non-responsiveness to 5-aminosalicylic acid in patients with ulcerative colitis identified using retrospective clinical study and Mendelian randomization.Scientific reports · 2025Article
- Systemic Immune-Inflammation Index: A Promising, Non-Invasive Biomarker for Crohn's Disease Activity and Severity Assessment.International journal of general medicine · 2025Article
- The Serum Biomarkers in Ulcerative Colitis.Medeniyet medical journal · 2024Article
- The epidemiological characteristics of invasive pulmonary aspergillosis and risk factors for treatment failure: a retrospective study.BMC pulmonary medicine · 2024Article
- A novel nomogram based on inflammation biomarkers for predicting radiation cystitis in patients with local advanced cervical cancer.Cancer medicine · 2024Article
- Predictive Value of MHR and NLR for Ulcerative Colitis Disease Activity.International journal of general medicine · 2024Article
- Article
- Hematological Composite Scores in Patients with Inflammatory Bowel Disease.Journal of clinical medicine · 2023Article
- A Nomogram-Based Model for Predicting the Risk of Severe Acute Cholangitis Occurrence.International journal of general medicine · 2023Article
- Precision medicine and drug optimization in adult inflammatory bowel disease patients.Therapeutic advances in gastroenterology · 2023Review
- Increased Systemic Immune-Inflammation Index Was Associated with Type 2 Diabetic Peripheral Neuropathy: A Cross-Sectional Study in the Chinese Population.Journal of inflammation research · 2023Article
- C-Reactive Protein-to-Albumin Ratio (CAR) and C-Reactive Protein-to-Lymphocyte Ratio (CLR) are Valuable Inflammatory Biomarker Combination for the Accurate Prediction of Periprosthetic Joint Infection.Infection and drug resistance · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Active and severe ulcerative colitis (UC) and non-response to 5-aminosalicylic acid (5-ASA) are related to poor outcomes and should be accurately identified. Several integrated inflammatory indexes are potentially useful to assess the disease severity in patients with acute or critical diseases but are underexplored in patients with UC. Methods: Patients with UC consecutively admitted to our hospital between January 2015 and December 2020 were retrospectively grouped according to the activity and severity of UC and response to 5-ASA. The neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), neutrophil-to-platelet ratio (NPR), platelet-to-albumin ratio (PAR), C-reactive protein-to-albumin ratio (CAR), and C-reactive protein-to-lymphocyte ratio (CLR) were calculated. The areas under receiver operating characteristic curves (AUC) were calculated. Results: Overall, 187 patients with UC were included, of whom 151 were active, 55 were severe, and 14 were unresponsive to 5-ASA. The active UC group had significantly higher NLR, PLR, SII, and PAR levels. SII had the greatest predictive accuracy for active UC, followed by PLR, PAR, and NLR (AUC = 0.647, 0.641, 0.634, and 0.626). The severe UC group had significantly higher NLR, PLR, SII, PAR, CAR, and CLR levels. CLR had the greatest predictive accuracy for severe UC, followed by CAR, PLR, SII, NLR, and PAR (AUC = 0.732, 0.714, 0.693, 0.669, 0.646, and 0.63). The non-response to the 5-ASA group had significantly higher CAR and CLR levels. CAR had a greater predictive accuracy for non-response to 5-ASA than CLR (AUC = 0.781 and 0.759). Conclusion: SII, CLR, and CAR may be useful for assessing the severity and progression of UC, but remain not optimal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.